Compare Harley-Davidson Inc (HOG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Novartis AG — how do they compare? Harley-Davidson Inc trades at $27.75 (market cap $2.93B), while Novartis AG trades at $156 (market cap $290.25B). The key difference: Novartis AG is far larger — about 99.1× Harley-Davidson Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| HOG | NVS | |
|---|---|---|
Market Cap | $2.93B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $168.62 |
52-Week Low | $17.19 | $113.50 |
Enterprise Value | $3.32B | $330.27B |
Dividend Yield | 2.64% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $27.85, up 4.78% today, with a bullish technical signal from moving averages and a neutral RSI near 69. Recent earnings show mixed results, with Q1 2026 missing estimates, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. The company is executing a turnaround strategy, including cost cuts and bringing Revolution Max engine production back to the U.S., amid positive retail sales growth in Q1 2026.
The outlook is cautious; while valuation ratios like P/E of 13.77 and P/B of 0.91 appear attractive, declining revenue and net income margins pose risks. Analyst consensus is mostly Hold (65.71%), with a price target of $23.40 below the current price, indicating skepticism about near-term growth despite operational initiatives.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
